JIANN-SHING JENG2021-12-222021-12-22200910196099https://www.scopus.com/inward/record.uri?eid=2-s2.0-63249089455&partnerID=40&md5=0cbb85b2776ab2232b5fb8a3681a6e6ehttps://scholars.lib.ntu.edu.tw/handle/123456789/590546[SDGs]SDG3fibrinolytic agent; tissue plasminogen activator; brain hemorrhage; cerebrovascular accident; community hospital; drug efficacy; drug safety; editorial; emergency physician; fibrinolytic therapy; functional status; health survey; human; medical specialist; neurology; postmarketing surveillance; Taiwan; tertiary health care; treatment outcome; United States; Fibrinolytic Agents; Hospitals, Community; Hospitals, Special; Humans; Injections, Intravenous; Stroke; Taiwan; Thrombolytic Therapy; Time Factors; Tissue Plasminogen Activatoreditorial195375672-s2.0-63249089455